Your browser doesn't support javascript.
loading
Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome.
Arachchillage, D R J; Efthymiou, M; Mackie, I J; Lawrie, A S; Machin, S J; Cohen, H.
Afiliación
  • Arachchillage DR; Haemostasis Research Unit, Department of Haematology, University College London, London, UK.
J Thromb Haemost ; 12(11): 1801-9, 2014 Nov.
Article en En | MEDLINE | ID: mdl-25196808
ABSTRACT

BACKGROUND:

Antiphospholipid antibodies may interfere with the anticoagulant activity of activated protein C (APC) to induce acquired APC resistance (APCr).

AIMS:

To investigate the frequency and characteristics of APCr by using recombinant human APC (rhAPC) and endogenous protein C activation in antiphospholipid syndrome (APS).

METHODS:

APCr was assessed in APS and non-APS venous thromboembolism (VTE) patients on warfarin and normal controls with rhAPC or Protac by thrombin generation. IgG anti-protein C and anti-protein S antibodies and avidity were assessed by ELISA.

RESULTS:

APS patients showed greater resistance to both rhAPC and Protac than non-APS patients and normal controls (median normalized endogenous thrombin potential inhibition) APS patients with rhAPC, 81.3% (95% confidence interval [CI] 75.2-88.3%; non-APS patients with rhAPC, 97.7% (95% CI 93.6-101.8%; APS patients with Protac, 66.0% (95% CI 59.5-72.6%); and non-APS patients with Protac, 80.7 (95% CI 74.2-87.2%). APS patients also had a higher frequency and higher levels of anti-protein C antibodies, with 60% (15/25) high-avidity antibodies. High-avidity anti-protein C antibodies were associated with greater APCr and with a severe thrombotic phenotype (defined as the development of recurrent VTE while patients were receiving therapeutic anticoagulation or both venous and arterial thrombosis). Twelve of 15 (80%) patients with high-avidity anti-protein C antibodies were classified as APS category I.

CONCLUSION:

Thrombotic APS patients showed greater APCr to both rhAPC and activation of endogenous protein C by Protac. High-avidity anti-protein C antibodies, associated with greater APCr, may provide a marker for a severe thrombotic phenotype in APS. However, in patients with category I APS, it remains to be established whether anti-protein C or anti-ß2 -glycoprotein I antibodies are responsible for APCr.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Proteína C / Síndrome Antifosfolípido / Anticuerpos Antifosfolípidos / Resistencia a la Proteína C Activada / Tromboembolia Venosa Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Idioma: En Revista: J Thromb Haemost Asunto de la revista: HEMATOLOGIA Año: 2014 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Proteína C / Síndrome Antifosfolípido / Anticuerpos Antifosfolípidos / Resistencia a la Proteína C Activada / Tromboembolia Venosa Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Idioma: En Revista: J Thromb Haemost Asunto de la revista: HEMATOLOGIA Año: 2014 Tipo del documento: Article